Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

By Giaccone Giuseppe   Iacona Renee   Fandi Abderrahim   Janas Mette   Ochs Judith   Herbst Roy   Johnson David  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 467-476

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite

Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 329-333

Science Publishers

Access to resources Recommend Favorite

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite